nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Methotrexate—testicular cancer	0.542	1	CbGbCtD
Brimonidine—Eye pain—Epirubicin—testicular cancer	0.00117	0.00256	CcSEcCtD
Brimonidine—Vision blurred—Cisplatin—testicular cancer	0.00117	0.00255	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00117	0.00255	CcSEcCtD
Brimonidine—Asthenia—Vinblastine—testicular cancer	0.00117	0.00255	CcSEcCtD
Brimonidine—Infection—Ifosfamide—testicular cancer	0.00117	0.00255	CcSEcCtD
Brimonidine—Lethargy—Methotrexate—testicular cancer	0.00115	0.00252	CcSEcCtD
Brimonidine—Nervous system disorder—Ifosfamide—testicular cancer	0.00115	0.00252	CcSEcCtD
Brimonidine—Skin disorder—Ifosfamide—testicular cancer	0.00114	0.00249	CcSEcCtD
Brimonidine—Osteoarthritis—Methotrexate—testicular cancer	0.00113	0.00247	CcSEcCtD
Brimonidine—Diabetes mellitus—Doxorubicin—testicular cancer	0.00113	0.00246	CcSEcCtD
Brimonidine—Dysgeusia—Etoposide—testicular cancer	0.00111	0.00243	CcSEcCtD
Brimonidine—Fatigue—Dactinomycin—testicular cancer	0.00111	0.00241	CcSEcCtD
Brimonidine—Hypotension—Ifosfamide—testicular cancer	0.0011	0.0024	CcSEcCtD
Brimonidine—Pain—Dactinomycin—testicular cancer	0.0011	0.00239	CcSEcCtD
Brimonidine—Eye pain—Doxorubicin—testicular cancer	0.00109	0.00237	CcSEcCtD
Brimonidine—Lethargy—Epirubicin—testicular cancer	0.00108	0.00236	CcSEcCtD
Brimonidine—Dizziness—Vinblastine—testicular cancer	0.00108	0.00235	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00107	0.00234	CcSEcCtD
Brimonidine—Osteoarthritis—Epirubicin—testicular cancer	0.00106	0.00231	CcSEcCtD
Brimonidine—Myalgia—Cisplatin—testicular cancer	0.00106	0.00231	CcSEcCtD
Brimonidine—Nausea—Chlorambucil—testicular cancer	0.00106	0.0023	CcSEcCtD
Brimonidine—Paraesthesia—Ifosfamide—testicular cancer	0.00106	0.0023	CcSEcCtD
Brimonidine—Anxiety—Cisplatin—testicular cancer	0.00105	0.0023	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00105	0.00229	CcSEcCtD
Brimonidine—Dyspnoea—Ifosfamide—testicular cancer	0.00105	0.00229	CcSEcCtD
Brimonidine—Somnolence—Ifosfamide—testicular cancer	0.00104	0.00228	CcSEcCtD
Brimonidine—Discomfort—Cisplatin—testicular cancer	0.00104	0.00228	CcSEcCtD
Brimonidine—Face oedema—Epirubicin—testicular cancer	0.00102	0.00223	CcSEcCtD
Brimonidine—Headache—Vinblastine—testicular cancer	0.00102	0.00223	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00101	0.00221	CcSEcCtD
Brimonidine—Fatigue—Ifosfamide—testicular cancer	0.00101	0.00221	CcSEcCtD
Brimonidine—Oedema—Cisplatin—testicular cancer	0.00101	0.00221	CcSEcCtD
Brimonidine—Hypersensitivity—Bleomycin—testicular cancer	0.00101	0.00221	CcSEcCtD
Brimonidine—Infection—Cisplatin—testicular cancer	0.00101	0.0022	CcSEcCtD
Brimonidine—Pain—Ifosfamide—testicular cancer	0.00101	0.00219	CcSEcCtD
Brimonidine—Loss of consciousness—Etoposide—testicular cancer	0.001	0.00218	CcSEcCtD
Brimonidine—Lethargy—Doxorubicin—testicular cancer	0.001	0.00218	CcSEcCtD
Brimonidine—Nervous system disorder—Cisplatin—testicular cancer	0.000994	0.00217	CcSEcCtD
Brimonidine—Cough—Etoposide—testicular cancer	0.000993	0.00217	CcSEcCtD
Brimonidine—Tachycardia—Cisplatin—testicular cancer	0.000989	0.00216	CcSEcCtD
Brimonidine—Asthenia—Bleomycin—testicular cancer	0.000987	0.00215	CcSEcCtD
Brimonidine—Skin disorder—Cisplatin—testicular cancer	0.000984	0.00215	CcSEcCtD
Brimonidine—Hypertension—Etoposide—testicular cancer	0.000982	0.00214	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—testicular cancer	0.00098	0.00214	CcSEcCtD
Brimonidine—Pruritus—Bleomycin—testicular cancer	0.000973	0.00212	CcSEcCtD
Brimonidine—Dry skin—Epirubicin—testicular cancer	0.00097	0.00212	CcSEcCtD
Brimonidine—Chest pain—Etoposide—testicular cancer	0.000968	0.00211	CcSEcCtD
Brimonidine—Nausea—Vinblastine—testicular cancer	0.000967	0.00211	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000962	0.0021	CcSEcCtD
Brimonidine—Discomfort—Etoposide—testicular cancer	0.000957	0.00209	CcSEcCtD
Brimonidine—Hypotension—Cisplatin—testicular cancer	0.000947	0.00207	CcSEcCtD
Brimonidine—Nasopharyngitis—Epirubicin—testicular cancer	0.000947	0.00207	CcSEcCtD
Brimonidine—Face oedema—Doxorubicin—testicular cancer	0.000946	0.00206	CcSEcCtD
Brimonidine—Hypersensitivity—Dactinomycin—testicular cancer	0.000945	0.00206	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000923	0.00201	CcSEcCtD
Brimonidine—Infection—Etoposide—testicular cancer	0.000922	0.00201	CcSEcCtD
Brimonidine—Asthenia—Dactinomycin—testicular cancer	0.00092	0.00201	CcSEcCtD
Brimonidine—Influenza—Epirubicin—testicular cancer	0.000915	0.002	CcSEcCtD
Brimonidine—Paraesthesia—Cisplatin—testicular cancer	0.00091	0.00199	CcSEcCtD
Brimonidine—Tachycardia—Etoposide—testicular cancer	0.000906	0.00198	CcSEcCtD
Brimonidine—Dyspnoea—Cisplatin—testicular cancer	0.000903	0.00197	CcSEcCtD
Brimonidine—Skin disorder—Etoposide—testicular cancer	0.000902	0.00197	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—testicular cancer	0.000898	0.00196	CcSEcCtD
Brimonidine—Bronchitis—Epirubicin—testicular cancer	0.00088	0.00192	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—testicular cancer	0.000876	0.00191	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000875	0.00191	CcSEcCtD
Brimonidine—Drowsiness—Methotrexate—testicular cancer	0.000872	0.0019	CcSEcCtD
Brimonidine—Depression—Methotrexate—testicular cancer	0.000869	0.0019	CcSEcCtD
Brimonidine—Hypotension—Etoposide—testicular cancer	0.000867	0.00189	CcSEcCtD
Brimonidine—Rash—Bleomycin—testicular cancer	0.000867	0.00189	CcSEcCtD
Brimonidine—Pain—Cisplatin—testicular cancer	0.000866	0.00189	CcSEcCtD
Brimonidine—Dermatitis—Bleomycin—testicular cancer	0.000866	0.00189	CcSEcCtD
Brimonidine—Hypersensitivity—Ifosfamide—testicular cancer	0.000866	0.00189	CcSEcCtD
Brimonidine—Conjunctivitis—Methotrexate—testicular cancer	0.000847	0.00185	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—testicular cancer	0.000847	0.00185	CcSEcCtD
Brimonidine—Asthenia—Ifosfamide—testicular cancer	0.000843	0.00184	CcSEcCtD
Brimonidine—Paraesthesia—Etoposide—testicular cancer	0.000834	0.00182	CcSEcCtD
Brimonidine—Pruritus—Ifosfamide—testicular cancer	0.000832	0.00181	CcSEcCtD
Brimonidine—Dyspnoea—Etoposide—testicular cancer	0.000828	0.00181	CcSEcCtD
Brimonidine—Somnolence—Etoposide—testicular cancer	0.000825	0.0018	CcSEcCtD
Brimonidine—Nausea—Bleomycin—testicular cancer	0.000817	0.00178	CcSEcCtD
Brimonidine—Drowsiness—Epirubicin—testicular cancer	0.000816	0.00178	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—testicular cancer	0.000814	0.00178	CcSEcCtD
Brimonidine—Rash—Dactinomycin—testicular cancer	0.000809	0.00176	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000801	0.00175	CcSEcCtD
Brimonidine—Fatigue—Etoposide—testicular cancer	0.0008	0.00175	CcSEcCtD
Brimonidine—Pain—Etoposide—testicular cancer	0.000794	0.00173	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—testicular cancer	0.000793	0.00173	CcSEcCtD
Brimonidine—Dizziness—Ifosfamide—testicular cancer	0.000777	0.0017	CcSEcCtD
Brimonidine—Pharyngitis—Methotrexate—testicular cancer	0.000777	0.0017	CcSEcCtD
Brimonidine—Sinusitis—Epirubicin—testicular cancer	0.000765	0.00167	CcSEcCtD
Brimonidine—Nausea—Dactinomycin—testicular cancer	0.000762	0.00166	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—testicular cancer	0.000755	0.00165	CcSEcCtD
Brimonidine—Visual impairment—Methotrexate—testicular cancer	0.000754	0.00165	CcSEcCtD
Brimonidine—Hypersensitivity—Cisplatin—testicular cancer	0.000747	0.00163	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—testicular cancer	0.000746	0.00163	CcSEcCtD
Brimonidine—Rash—Ifosfamide—testicular cancer	0.000741	0.00162	CcSEcCtD
Brimonidine—Dermatitis—Ifosfamide—testicular cancer	0.00074	0.00162	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—testicular cancer	0.000734	0.0016	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—testicular cancer	0.000734	0.0016	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—testicular cancer	0.000731	0.0016	CcSEcCtD
Brimonidine—Asthenia—Cisplatin—testicular cancer	0.000727	0.00159	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—testicular cancer	0.000727	0.00159	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—testicular cancer	0.000726	0.00159	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—testicular cancer	0.00071	0.00155	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—testicular cancer	0.000708	0.00155	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—testicular cancer	0.000707	0.00154	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—testicular cancer	0.000706	0.00154	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—testicular cancer	0.000705	0.00154	CcSEcCtD
Brimonidine—Nausea—Ifosfamide—testicular cancer	0.000698	0.00152	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—testicular cancer	0.00069	0.00151	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—testicular cancer	0.000686	0.0015	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—testicular cancer	0.000684	0.00149	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—testicular cancer	0.000684	0.00149	CcSEcCtD
Brimonidine—Erythema—Methotrexate—testicular cancer	0.000681	0.00149	CcSEcCtD
Brimonidine—Flushing—Epirubicin—testicular cancer	0.00068	0.00148	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—testicular cancer	0.00068	0.00148	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—testicular cancer	0.000679	0.00148	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—testicular cancer	0.000673	0.00147	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—testicular cancer	0.000667	0.00146	CcSEcCtD
Brimonidine—Asthenia—Etoposide—testicular cancer	0.000666	0.00145	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—testicular cancer	0.000665	0.00145	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—testicular cancer	0.000662	0.00144	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—testicular cancer	0.00066	0.00144	CcSEcCtD
Brimonidine—Pruritus—Etoposide—testicular cancer	0.000657	0.00143	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—testicular cancer	0.000654	0.00143	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—testicular cancer	0.000653	0.00143	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—testicular cancer	0.000642	0.0014	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—testicular cancer	0.000642	0.0014	CcSEcCtD
Brimonidine—Rash—Cisplatin—testicular cancer	0.000639	0.00139	CcSEcCtD
Brimonidine—Dermatitis—Cisplatin—testicular cancer	0.000638	0.00139	CcSEcCtD
Brimonidine—Erythema—Epirubicin—testicular cancer	0.000638	0.00139	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—testicular cancer	0.000633	0.00138	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—testicular cancer	0.000629	0.00137	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—testicular cancer	0.000629	0.00137	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—testicular cancer	0.000624	0.00136	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—testicular cancer	0.000615	0.00134	CcSEcCtD
Brimonidine—Dizziness—Etoposide—testicular cancer	0.000614	0.00134	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—testicular cancer	0.000612	0.00134	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000611	0.00133	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—testicular cancer	0.000605	0.00132	CcSEcCtD
Brimonidine—Nausea—Cisplatin—testicular cancer	0.000602	0.00131	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—testicular cancer	0.000601	0.00131	CcSEcCtD
Brimonidine—Cough—Methotrexate—testicular cancer	0.000595	0.0013	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—testicular cancer	0.000594	0.0013	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—testicular cancer	0.00059	0.00129	CcSEcCtD
Brimonidine—Rash—Etoposide—testicular cancer	0.000585	0.00128	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—testicular cancer	0.000585	0.00128	CcSEcCtD
Brimonidine—Headache—Etoposide—testicular cancer	0.000582	0.00127	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—testicular cancer	0.00058	0.00127	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—testicular cancer	0.00058	0.00127	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—testicular cancer	0.00058	0.00127	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—testicular cancer	0.000578	0.00126	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000576	0.00126	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—testicular cancer	0.000573	0.00125	CcSEcCtD
Brimonidine—Syncope—Epirubicin—testicular cancer	0.000572	0.00125	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—testicular cancer	0.000563	0.00123	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—testicular cancer	0.00056	0.00122	CcSEcCtD
Brimonidine—Cough—Epirubicin—testicular cancer	0.000556	0.00121	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—testicular cancer	0.000556	0.00121	CcSEcCtD
Brimonidine—Infection—Methotrexate—testicular cancer	0.000552	0.00121	CcSEcCtD
Brimonidine—Nausea—Etoposide—testicular cancer	0.000551	0.0012	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—testicular cancer	0.00055	0.0012	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—testicular cancer	0.000545	0.00119	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—testicular cancer	0.000543	0.00118	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—testicular cancer	0.000543	0.00118	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—testicular cancer	0.000543	0.00118	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—testicular cancer	0.000541	0.00118	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—testicular cancer	0.00054	0.00118	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000539	0.00118	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—testicular cancer	0.000536	0.00117	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—testicular cancer	0.000531	0.00116	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—testicular cancer	0.000529	0.00115	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—testicular cancer	0.000521	0.00114	CcSEcCtD
Brimonidine—Oedema—Epirubicin—testicular cancer	0.00052	0.00114	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—testicular cancer	0.00052	0.00113	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—testicular cancer	0.000519	0.00113	CcSEcCtD
Brimonidine—Infection—Epirubicin—testicular cancer	0.000517	0.00113	CcSEcCtD
Brimonidine—Cough—Doxorubicin—testicular cancer	0.000515	0.00112	CcSEcCtD
Brimonidine—Shock—Epirubicin—testicular cancer	0.000512	0.00112	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—testicular cancer	0.00051	0.00111	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—testicular cancer	0.000509	0.00111	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—testicular cancer	0.000508	0.00111	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000507	0.00111	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—testicular cancer	0.000505	0.0011	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—testicular cancer	0.000503	0.0011	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—testicular cancer	0.000502	0.0011	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—testicular cancer	0.000502	0.0011	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—testicular cancer	0.000502	0.0011	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—testicular cancer	0.000501	0.00109	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—testicular cancer	0.000499	0.00109	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000499	0.00109	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—testicular cancer	0.000496	0.00108	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—testicular cancer	0.000496	0.00108	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—testicular cancer	0.000494	0.00108	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—testicular cancer	0.000491	0.00107	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—testicular cancer	0.000489	0.00107	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—testicular cancer	0.000486	0.00106	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—testicular cancer	0.000481	0.00105	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00048	0.00105	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—testicular cancer	0.000479	0.00105	CcSEcCtD
Brimonidine—Infection—Doxorubicin—testicular cancer	0.000478	0.00104	CcSEcCtD
Brimonidine—Pain—Methotrexate—testicular cancer	0.000475	0.00104	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000474	0.00103	CcSEcCtD
Brimonidine—Shock—Doxorubicin—testicular cancer	0.000474	0.00103	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—testicular cancer	0.000472	0.00103	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—testicular cancer	0.000471	0.00103	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—testicular cancer	0.00047	0.00103	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—testicular cancer	0.000468	0.00102	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—testicular cancer	0.000467	0.00102	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—testicular cancer	0.000464	0.00101	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—testicular cancer	0.000463	0.00101	CcSEcCtD
Brimonidine—Dyspepsia—Epirubicin—testicular cancer	0.000458	0.001	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—testicular cancer	0.00045	0.000982	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000449	0.00098	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—testicular cancer	0.000449	0.000979	CcSEcCtD
Brimonidine—Pain—Epirubicin—testicular cancer	0.000445	0.000971	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000439	0.000957	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—testicular cancer	0.000435	0.00095	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—testicular cancer	0.000432	0.000943	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—testicular cancer	0.000429	0.000937	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—testicular cancer	0.000428	0.000934	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—testicular cancer	0.000424	0.000925	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000416	0.000907	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—testicular cancer	0.000415	0.000906	CcSEcCtD
Brimonidine—Pain—Doxorubicin—testicular cancer	0.000412	0.000898	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—testicular cancer	0.00041	0.000894	CcSEcCtD
Brimonidine—Asthenia—Methotrexate—testicular cancer	0.000399	0.000871	CcSEcCtD
Brimonidine—Pruritus—Methotrexate—testicular cancer	0.000393	0.000858	CcSEcCtD
Brimonidine—Hypersensitivity—Epirubicin—testicular cancer	0.000383	0.000837	CcSEcCtD
Brimonidine—Asthenia—Epirubicin—testicular cancer	0.000373	0.000815	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—testicular cancer	0.000368	0.000803	CcSEcCtD
Brimonidine—Dizziness—Methotrexate—testicular cancer	0.000368	0.000802	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—testicular cancer	0.000355	0.000774	CcSEcCtD
Brimonidine—Rash—Methotrexate—testicular cancer	0.000351	0.000765	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—testicular cancer	0.00035	0.000764	CcSEcCtD
Brimonidine—Headache—Methotrexate—testicular cancer	0.000348	0.00076	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—testicular cancer	0.000345	0.000754	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—testicular cancer	0.000344	0.000751	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—testicular cancer	0.000341	0.000743	CcSEcCtD
Brimonidine—Nausea—Methotrexate—testicular cancer	0.00033	0.000721	CcSEcCtD
Brimonidine—Rash—Epirubicin—testicular cancer	0.000328	0.000716	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—testicular cancer	0.000328	0.000715	CcSEcCtD
Brimonidine—Headache—Epirubicin—testicular cancer	0.000326	0.000711	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—testicular cancer	0.000318	0.000695	CcSEcCtD
Brimonidine—Nausea—Epirubicin—testicular cancer	0.000309	0.000674	CcSEcCtD
Brimonidine—Rash—Doxorubicin—testicular cancer	0.000304	0.000662	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—testicular cancer	0.000303	0.000662	CcSEcCtD
Brimonidine—Headache—Doxorubicin—testicular cancer	0.000302	0.000658	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—testicular cancer	0.000286	0.000624	CcSEcCtD
